Results 191 to 200 of about 214,611 (264)

Clinical Translation of Patient‐Derived Organoids: Perspectives for Personalized Therapy in Cancer

International Journal of Cancer, EarlyView.
ABSTRACT Patient‐derived organoids (PDO) are accelerating precision medicine. These biological platforms allow for the autologous in vitro expansion of material from cancer patients in a considerably short period of time. These three‐dimensional models can faithfully recapitulate aspects of tissue heterogeneity, architecture, and relevant cellular ...
Haiyan Yue, Daniele Carchidi, Philipp Schmucker, Roland Seiler, Bernhard Kiss, Catarina Macedo‐Silva, Marianna Kruithof‐de Julio   +6 more
wiley   +1 more source

Clinical Decision-Making After Receptor Conversion Following Neoadjuvant Therapy in Breast Cancer: A Three-Strategy Framework. [PDF]

J Clin Med
Pogoda K, Czopowicz M, Olszewski W, Durzynska M, Wysocki PJ.   +4 more
europepmc   +1 more source

Second Breast‐Conserving Treatment for Ipsilateral Breast Tumor Recurrence: A Review of Patient Selection, Reirradiation Techniques, and Clinical Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Local recurrence after primary breast cancer treatment remains a complex clinical scenario in patients previously treated with breast‐conserving therapy and radiotherapy. For decades, salvage mastectomy was considered the standard treatment for ipsilateral breast tumor recurrence, largely because of concerns about local control after repeat ...
Cezara Cheptea, Youlia Kirova, Radu Iulian Mitrica, Mihaela Badea, Pierre Loap   +4 more
wiley   +1 more source

¹⁷⁷Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer. [PDF]

Mol Biomed
Santos L, Hrynchak I, Sereno J, Ferreira HRS, Silva M, Fonseca A, Almeida R, Teixeira P, Abrunhosa AJ, Gomes CMF.   +9 more
europepmc   +1 more source

Estimation of Subtype‐Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology‐Inspired Natural History Models

International Journal of Cancer, EarlyView.
ABSTRACT Breast cancer progression varies across molecular subtypes, influencing detection rates and prognosis. Differences in the proportion of interval cancers (PIC)—cancers detected symptomatically between scheduled screening rounds—have been observed across subtypes, likely reflecting heterogeneity in tumour growth dynamics. We applied a continuous‐
Letizia Orsini, Yuqi Zhang, Kamila Czene, Keith Humphreys   +3 more
wiley   +1 more source

HER2-directed therapy with Trastuzumab deruxtecan in recurrent mucinous ovarian carcinoma: complete clinical response and response to rechallenge. [PDF]

Gynecol Oncol Rep
Krivenko O, Diaz N, Marcus J, Musa F.
europepmc   +1 more source

Impact of Single‐Cell RNA Reference Selection for the Deconvolution of Breast Cancer Spatial Transcriptomics Datasets

International Journal of Cancer, EarlyView.
ABSTRACT Spot‐based spatial transcriptomics (ST) allows for unbiased gene expression analysis within tissue architecture, overcoming the limitations of single‐cell RNA sequencing (scRNA‐seq) by preserving spatial context. However, the high spatial resolution in ST leads to cellular heterogeneity within spots, requiring computational deconvolution to ...
Stefan Altendorfer, Scott J. Walker, Carsten O. Daub   +2 more
wiley   +1 more source

Response of HER2 positive gallbladder adenocarcinoma to trastuzumab emtansine (T-DM1): a case report and literature review. [PDF]

Front Oncol
Ling W, Zang J, Xiang F, Liu X, Chen S.
europepmc   +1 more source